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APPENDIX B
DRAFT
AUGUST 1, 1997
AN ACT concerning
CONSENT TO RESEARCH

-

PROTECTION OF DECISIONALLY

INCAPACITATED INDIVIDUALS

SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY
OF MARYLAND, That the Laws of Maryland read as follows:
ARTICLE -

HEALTH-GENERAL

Title 20. Miscellaneous Health Provisions.
Subtitle 5. Consent for Research Involving Decisionally
Incapacitated Individuals.
20-501.

LEGISLATIVE FINDINGS.

The General Assembly finds that:
(a)
All research involving human subjects in this State, including research involving decisionally incapacitated individuals, should
be conducted with the utmost respect for the well-being and dignity of
each research subject.
(b)
Except as otherwise specifically authorized under federal
or State law, all research involving human subjects in this State should
be conducted only after each subject provides informed consent to
participation in the research.
(c)
Research involving decisionally incapacitated individuals
may be essential under some circumstances if science is to understand
and ultimately combat diseases of the brain, including Alzheimer's
Disease, severe psychiatric disorders, severe trauma, stroke, other
causes of decisional incapacity, and the medical problems that are associated with these conditions and disorders.
(d)
Researchers should seek to enroll decisionally incapacitated individuals as research subjects only if the research is expected
to yield generalizable knowledge important to the understanding or
amelioration of the subjects' disorder or condition and related medical problems, and the knowledge cannot be obtained without their
participation.
20-502. DEFINITIONS.
(a)
In this subtitle, the following terms have the meanings
indicated.
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(b)
"Advance directive authorizing research participation" means
an advance directive made in accordance with §5-602 of this article
that states a desire of an individual to participate in research.
"Assent' means an individual's affirmative agreement to
(c)
participate in research.
"Common Rule" means the federal regulations governing
(d)
the protection of human subjects in research codified at 45 C.F.R.
Part 46, Subpart A.
(e) (1) "Decisionally incapacitated individual" means an individual
who is at least 18 years of age and who cannot give a valid informed
consent for research participation because the individual cannot sufficiently understand the nature, extent, or probable consequences of
the proposed research participation, cannot make a sufficient evaluation of burdens, risks, and benefits of the proposed research participation, or cannot communicate a decision.
(2) An individual who is able to communicate by means other
than speech may not be considered incapable of giving informed consent solely by reason of the inability to speak.
(f)
"Disinterested' means:
(1) not participating in any way, including authorship of publications, in the research concerning which an individual performs duties under this subtitle; and
(2) not having any investment or other financial interest in
any business entity sponsoring the research.
(g)
"Health care agent' means a disinterested adult appointed
by an individual under an advance directive and authorized under the
Health Care Decisions Act to make health care decisions for the
individual.
(h)
"Health Care Decisions Act' means Title 5, Subtitle 6 of this
article.
(i)
"Informed consent" means:
(1) the voluntary agreement by an individual to participate in
research following disclosure to the individual of all relevant information as determined by an IRB pursuant to the Common Rule and this
subtitle; or
(2) if an individual is a decisionally incapacitated individual,
the voluntary agreement by a legally authorized representative for the
individual to participate in research following disclosure to the legally
authorized representative of all relevant information as determined by
an IRB pursuant to the Common Rule and this subtitle.
(j)
"Investigato' means a person who conducts research by
means of:
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(1) physical procedures by which data are gathered from a living individual;
(2) manipulation of an individual or the individual's
environment;
(3) communication or interpersonal contact between an investigator and individual; or
(4) gathering individually identifiable private information,including information about behavior that occurs in a context in which
an individual can reasonably expect that no observation or recording
is taking place and information which has been provided for specific
purposes by an individual and which the individual can reasonably
expect will not be made public.
(k)
"IRH' means an institutional review board whose membership and processes comply with the requirements of the Common
Rule.
(1)
"Legally authorized representative' means an individual authorized under this subtitle to give consent to a decisionally incapacitated individual's participation in research.
(m)
"Medicalbest interest" means that the burdens to the individual resulting from participation in research are determined by the
legally authorized representative to be acceptable in relation to the
potential medical benefits to the individual resulting from the individual's participation in research, taking into account:
(1) the effect of the participation in research on the physical,
emotional, and cognitive functions of the individual;
(2) the degree of physical pain or discomfort, psychological
distress, or loss of dignity caused to the individual by the participation
in research;
(3) the prognosis of the individual;
(4) the risks, side effects, and benefits of the participation in
research, compared to the risks, side effects, and benefits of standard
treatment, if any;
(5) the religious beliefs and basic values of the individual, to
the extent these may assist the legally authorized representative in determining medical best interest.
(n) (I) "Minimal risk" means that the probability and magnitude
of harm or discomfort anticipated in the research, including psychological harm and loss of privacy or other aspects of personal dignity,
are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or
psychological examinations or tests.
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(2) Research presenting "minimal risk" includes types of research that are:
(i) identified by the United States Department of Health
and Human Services as suitable for expedited IRB review procedures;
or
(ii) designated as "minimal risk" in a regulation of the
Secretary of Health and Mental Hygiene.
(o) (1) "Minor increase over minimal risk" means that the
probability and magnitude of harm or discomfort anticipated in the
research, including psychological harm and loss of privacy or other
aspects of personal dignity, are only slightly greater in and of themselves than those ordinarily encountered in daily life or during the
performance of routine physical or psychological examinations or
tests.
(2) Research presenting a "minor increase over minimal risk"
includes types of research designated as "minor increase over minimal
risk" in a regulation of the Secretary of Health and Mental Hygiene.
(p)
"Monitor" means a disinterested adult who is designated
by an IRB, in accordance with -this subtitle, to monitor the informed
consent process when a research agent is considering whether to give
informed consent to participation by decisionally incapacitated individual in research that, as determined by an IRB:
(1) does not present a reasonable prospect of direct medical
benefit; and
(2) presents more than a minor increase over minimal risk.
(q)
"Proxy decision make?' means a disinterested adult who is
designated by an IRB to consider whether to give informed consent,
in accordance with this subtitle, for a decisionally incapacitated individual who had executed an advance directive authorizing research
participation to participate in research that, as determined by an IRB,
presents:
(1) a reasonable prospect of direct medical benefit; or
(2) minimal risk.
(r)
"Reasonable prospect of direct medical benefit' means that, on
the basis of scientific evidence, a realistic possibility exists that an individual's medical condition would be improved as a direct result of participation in research, including ameliorating symptoms or avoiding
side effects of standard therapy.
(s)
"Research" means a systematic investigation including development, testing, and evaluation, designed to develop or contribute
to generalizable knowledge.
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(t)
"Research agent' means a disinterested adult who, under an
advance directive authorizing research participation, is expressly authorized to make decisions regarding an individual's participation in
research, whether or not the research agent is also a health care agent
or surrogate.
(u)
"Surrogate" means a disinterested adult who is neither a
research agent nor a health care agent but who is authorized by the
Health Care Decisions Act to make health care decisions for an
individual.
20-503. SCOPE OF SUBTITLE.
(a) (1) Except as provided in subsection (b) of this section, all
research in this State involving a decisionally incapacitated individual
shall comply with this subtitle.
(2) Except as provided in subsection (b) of this section, research involving a decisionally incapacitated individual that is not expressly authorized in this subtitle is prohibited.
(b)
An investigator need not comply with this subtitle if research involving a decisionally incapacitated individual:
(1) is exempt under 45 C.F.R. §46.101(b) from the requirements of the Common Rule;
(2) concerns treatment for a life-threatening emergency and
is conducted in accordance with regulations of the United States Food
and Drug Administration or a waiver of informed consent by the
United States Department of Health and Human Services; or
(3) (i) is limited to the study of existing data, documents,
records, pathological specimens, or diagnostic specimens;
(ii). will be conducted under procedures approved by an
IRB sufficient to safeguard the privacy of the individual whose data,
documents, or specimens are studied and any other identifiable individuals about whom personal information might be learned as a result
of the research; and
(iii) is granted a waiver of informed consent by the IRB
pursuant to 45 C.F.R. §46.116(d).
(c) (1) Except as provided in paragraph (2) of this subsection,
nothing in this subtitle affects research that involves an individual with
decisional capacity who has given informed consent to become a subject of the research.
(2) If an individual gave informed consent for research participation but becomes a decisionally incapacitated individual during the
course of the research, the individual's further participation in the
research is subject to this subtitle.
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20-504. PERMISSIBLE RESEARCH - GENERAL CONDITIONS.
(a)
An investigator who conducts research involving decisionally incapacitated individuals shall comply with all requirements applicable to an investigator under the Common Rule and this subtitle.
(b) (1) An investigator who plans to involve decisionally incapacitated individuals as research subjects shall obtain approval from an
IRB to conduct the research with this group of subjects.
(2) Research that is planned to involve a group of decisionally incapacitated individuals as research subjects shall relate directly
to:
(i) the condition that has resulted in the decisional incapacity of those individuals;
(ii) a demonstrated or reasonably predicted relationship between that condition and any other medical condition of those individuals; or
. (iii) an assessment of the efficacy of an intervention already
used in clinical practice to treat a condition or relationship described
in subparagraphs (i) or (ii) of this paragraph.
(c) (1) An investigator who did not plan to involve decisionally
incapacitated individuals as research subjects and therefore did not
obtain approval from an IRB to do so nevertheless may involve a particular decisionally incapacitated individual as a research subject if:
(i) the research, as approved by the IRB, holds out a reasonable prospect of direct medical benefit to the research subjects;
(ii) the individual meets all applicable criteria for participation in the research;
(iii) in accordance with §20-510, the investigator obtains
the informed consent of a legally authorized representative of the individual or of a court or guardian of the person; and
(iv) the investigator promptly notifies the IRB that the individual is participating in the research.
(2) If, in light of the criteria for participation in the research,
the investigator anticipates that other decisionally incapacitated individuals may become involved in the research in the future, the investigator shall obtain approval from an IRB for their participation.
20-505. INVESTIGATOR'S DISCLOSURE TO IRB.
When an investigator plans to involve decisionally incapacitated
individuals as research subjects, the investigator shall:
(1) describe to an IRB the group of decisionally incapacitated
individuals who will be eligible to be involved;
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(2) explain to the IRB why the proposed research cannot be
conducted without the involvement of this group of decisionally incapacitated individuals;
(3) provide the IRB with the results of any prior review of the
scientific merits of the proposed research or state to the IRB that the
scientific merits of the proposed research have not been reviewed;
(4) inform the IRB whether any other IRB has failed to approve the research or substantially equivalent research proposed by
the investigator;
(5) inform the IRB whether any investigator involved in the
research has, within the preceding five years, been found by an agency
of the United States, this State, or another state to have knowingly
violated this subtitle or any federal or state law protecting the rights
and welfare of decisionally incapacitated individuals in research;
(6) describe to the IRB the procedures by which the health
and safety of the research subjects are to be monitored during the
course of the research, including appropriate consultation with the
attending physicians of the research subjects;
(7) describe to the IRB:
(i) how legally authorized representatives may observe
the research or otherwise learn about the experience of decisionally
incapacitated individuals in the research;
(ii) whether a consent for further research participation
will be sought from legally authorized representatives at any point
during the research; and
(iii) what procedures are to be used for periodic confirmation that the individual remains willing to participate in the research; and
(8) obtain approval from the IRB to conduct the research.

20-506.

IRB - IN GENERAL.
In considering whether to approve research in which an investigator plans to involve decisionally incapacitated individuals, an IRB
shall:
(1) comply with all requirements applicable to an IRB under
the Common Rule, including its requirements for membership, and
under this subtitle;
(2) consider whether additional safeguards, beyond those
generally required by the Common Rule, should be adopted to protect the rights and welfare of the decisionally incapacitated individuals
who will be research subjects;
RESPONSIBILITIES OF AN
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(3) review the research to determine that the proposed procedures do not unnecessarily expose decisionally incapacitated individuals to risk; and
(4) verify that the investigator has provided the IRB with the
information required by §20-505.
20-507.

RESPONSIBILITIES OF AN

IRB

-

DETERMINATION AND DESCRIP-

TION OF BENEFITS AND RISKS.

(a) (1) (i) If an investigator seeks approval for research in which
a group of decisionally incapacitated individuals are planned to be
involved, an IRB shall determine and state in its minutes whether the
research presents a reasonable prospect of direct medical benefit to
the group of subjects as a whole.
(ii) In considering whether the research presents a reasonable prospect of direct medical benefit to the group of subjects as
a whole, the IRB shall take into account the relevant scientific evidence available to it and the nature of the research design, including
the effect of any placebo control.
(2) If research presents a reasonable prospect of direct medical benefit to the group of subjects, the IRB shall ensure that materials to be made available to legally authorized representatives as part of
the informed consent process fairly describe the risks and benefits of
research participation, including the extent to which the research
adds to the probability or magnitude of harm or discomfort that the
individuals could be expected to experience if they did not participate
in the research.
(b) (1) If the IRB determines that the research presents no reasonable prospect of direct medical benefit to a group of research subjects, the IRB shall further determine and state in its minutes whether
the research presents, to that group as a whole, a level of risk that is:
(i) minimal risk;
(ii) a minor increase over minimal risk; or
(iii) more than a minor increase over minimal risk
(2) An IRB shall determine that research presents more than
a minor increase over minimal risk if, as a result of research participation, the subjects would be exposed to more than a remote possibility
of:
(i) severe or prolonged pain or discomfort; or
(ii) clinically significant deterioration in a medical
condition.
(3) The IRB shall ensure that materials to be made available
to legally authorized representatives as part of the informed consent
process fairly describe the risks of research participation, including
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the extent to which the research adds to the probability or magnitude
of harm or discomfort that the individuals could be expected to experience if they did not participate in the research.
20-508. RESPONSIBILITIES OF AN IRB - OTHER SAFEGUARDS.
(a)
If the IRB learns that an investigator involved in research
in which decisionally incapacitated individuals are intended to be the
subject has, within the preceding five years, been found by an agency
of the United States, this State, or another state to have knowingly
violated this subtitle or any federal or state law protecting the rights
and welfare of decisionally incapacitated individuals in research, the
IRB shall:
(1) decline to approve the research; and
(2) provide the Secretary of Health and Mental Hygiene and
the Attorney General with the information available to the IRB concerning the violation.
(b)
An IRB shall establish standards and procedures under
which a health care agent shall document, in accordance with §20515(c), the direct and explicit evidence of a decisionally incapacitated
individual's wish to participate in research.
(c)
In addition to the review of research at periodic intervals
required by the Common Rule, an IRB may at any time suspend or
withdraw its approval of research or suspend the accrual of additional
research subjects if the IRB concludes that:
(1) continuation of research may result in unanticipated
harm to research subjects; or
(2) an investigator has failed to:
(i) carry out properly the investigator's responsibilities
under the Common Rule and this subtitle; or
(ii) comply with the determinations of the IRB.
20-509. CONFORMING RESEARCH TO IRB DETERMINATIONS.
(a)
If an IRB has determined that research presents a reasonable prospect of direct medical benefit to a group of research subjects,
an investigator shall:
(1) involve in the research only individuals who fall within
that group; and
(2) discontinue the involvement in the research of any individual for whom the research no longer presents a reasonable prospect of direct medical benefit.
(b)
If an IRB has determined that research presents a particular level of risk to a group of research subjects, an investigator shall:
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(1) involve in the research only individuals who fall within
that group; and
(2) immediately discontinue the involvement in the research
of any individual for whom the research has presented a higher level
of risk.
(c)
An investigator shall immediately report to the IRB any
unexpected serious harm to a research subject resulting from participation in the research.
20-510. INFORMED CONSENT.
(a)
An investigator shall provide a legally authorized representative with all of the information deemed necessary by an IRB for
informed consent.
(b)
As part of the informed consent process, an investigator
shall fairly describe:
(1) all material risks and direct medical benefits, if any, reasonably foreseeable from participation in the research;
(2) if the research involves an alternative to a standard form
of treatment, the risks and benefits of the research alternative compared to the standard treatment; and
(3) randomization, the use of a placebo, or other aspects of
the control element of a research desigr.
(c)(1) Prior to involving a decisionally incapacitated individual
in research, an investigator shall obtain the informed consent of a legally authorized representative of an individual, as provided in this
subtitle, or of a court or guardian of the person.
(2) Unless documentation requirements have been waived by
the IRB under 45 C.F.R. §46.117(c), the investigator shall document
the consent by obtaining a written consent form signed by the legally
authorized representative.
(d)
If a research subject was a decisionally incapacitated individual when first involved in research, but later is able to give informed consent, the investigator may riot involve the individual in
further research without the individual's informed consent.
20-511. SUBJECT ASSENT.
(a)
Unless the individual is unconscious, prior to the participation in research of a decisionally incapacitated individual, an investigator shall tell the individual, in a manner appropriate to the
individual's capacity for understanding:
(i) the fact that he or she is being asked to participate in
research; and
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(ii) the name of the legally authorized representative
who has consented to the individual's participation.
(b)
An investigator shall obtain the assent of any decisionally
incapacitated individual who is capable of giving assent prior to involving the individual in research.
(c) (1) Nothing in this subtitle authorizes an investigator to:
(i) involve an individual in an action related to research
if the investigator is aware that the individual has expressed disagreement with the action; or
(ii) compel a decisionally incapacitated individual to perform an action related to the research if the individual refuses to take
the action after being asked to do so.
(2) An investigator may take reasonable, noncoercive steps to
encourage a decisionally incapacitated individual to reconsider a refusal of assent or refusal to perform an action related to the research.
20-512. EFFECT OF GUARDIANSHIP.
(a) Except as provided in subsection (c), nothing in this subtitle
affects the authority of a court or a guardian of the person appointed
under Title 13, Subtitle 7 of the Courts and Judicial Proceedings
Article.
(b) Notwithstanding the authority given in this subtitle to a legally authorized representative, if a guardian of the person has been
appointed for the individual and has specifically been granted authority to make decisions about a decisionally incapacitated individual's
participation in research, the guardian, subject to the court's supervision, shall have exclusive authority to make these decisions.
(c) A guardian of the person may not give informed consent for
a decisionally incapacitated individual to participate in research unless the research, as approved by the IRB, presents:
(1) a reasonable prospect of direct medical benefit to the individual; or
(2) no more than a minor increase over minimal risk to the
individual.
20-513.

AUTHORITY TO GIVE INFORMED CONSENT -

DIRECT MEDICAL

BENEFIT.

(a)
This section applies to research that, as determined by an
IRB, presents a reasonable prospect of direct medical benefit to the
research subjects.
(b)
A research agent may consent to a decisionally incapacitated individual's participation in research described in subsection (a)
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(1) after taking into account the risks and benefits of research participation compared to the risks and benefits of any treatment alternatives outside of the research, the research agent
concludes that participation in the research is in the individual's medical best interest; and
(2) the research agent does not have reason to believe that
the individual would have declined to participate in the research were
the individual able to give informed consent.
A health care agent may consent to a decisionally incapac(c)
itated individual's participation in research described in subsection
(a) if:
(1) a research agent is not available;
(2) after taking into account the risks and benefits of research
participation compared to the risks and benefits of any treatment alternatives outside of the research, the health care agent concludes
that participation in the research is in the individual's medical best
interest; and
(3) the health care agent does not have reason to believe that
the individual would have declined to participate in the research were
the individual able to give informed consent.
(d) (1) A surrogate may consent to a decisionally incapacitated
individual's participation in research described in subsection (a) if(i) neither a research agent nor a health care agent is
available;
(ii) after taking into account the risks and benefits of research participation compared to the risks and benefits of any treatment alternatives outside of the research, the surrogate concludes
that participation in the research is in the individual's medical best
interest; and
(iii) the surrogate does not have reason to believe that
the individual would have declined to participate in the research were
the individual able to give informed consent.
(2) If surrogates with equal decision making priority under
the Health Care Decisions Act disagree about the individual's participation in the research, the disagreement shall be resolved in accordance with §5-605(b) of this article.
A proxy decision maker designated by an IRB in accord(e)
ance with §20-519 may consent to a decisionally incapacitated individual's participation in research described in subsection (a) if:
(1) no health care agent, research agent, or surrogate is
available;
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(2) the research is unambiguously included in the individual's advance directive authorizing research participation; and
(3) after taking into account the risks and benefits of research
participation compared to the risks and benefits of any treatment al-

ternatives outside of the research, the proxy decision maker concludes
that participation in the research is in the individual's medical best
interest.
(f)
In considering whether an individual would have declined
to participate in research were the individual able to give informed
consent, a research agent, health care agent, surrogate, or proxy decision maker may take into account any relevant information,
including:
(1) any expressed preferences of the individual regarding participation in the kind of research at issue;
(2) any expressed preferences of the individual about research participation generally;
(3) any religious or moral beliefs or personal values of the individual in relation to research participation;
(4) any behavioral or other manifestations of the attitude of
the individual toward research participation, including prior participation in research;
(5) any reactions of the individual to another individual's research participation; and
(6) any statements of the individual about the effect of research participation on the individual's family or on others who have
the same medical condition.
20-514.

AUTHORITY TO GIVE INFORMED CONSENT -

NO DIRECT MEDICAL

BENEFIT, MINIMAL RISK.

(a)
This section applies to research involving decisionally incapacitated individuals that, as determined by an IRB:
(1) does not present. a reasonable prospect of direct medical
benefit to the research subjects; and
(2) presents no greater than minimal risk to the research
subjects.
(b)
A research agent, if available, may consent to a decisionally incapacitated individual's participation in research described in
subsection (a) if the research agent has reason to believe that the individual would have consented to participate in the research were the
individual able to give informed consent.
(c)
If a research agent is not available, a health care agent
may consent to a decisionally incapacitated individual's participation
in research described in subsection (a) if the health care agent has
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reason to believe that the individual would have consented to participate in the research were the individual able to give informed
consent.
(d) (1) If neither a research agent nor a health care agent is available, a surrogate may consent to a decisionally incapacitated individual's participation in research described in subsection (a) if the
surrogate has reason to believe that the individual would have consented to participate in the research were the individual able to give
informed consent.
(2) If two or more surrogates with equal decision making priority under the Health Care Decisions Act are available, the individual
may participate in the research only if all surrogates jointly consent to
the individual's participation.
(e)
If no research agent, health care agent, or surrogate is
available, a proxy decision maker may consent to a decisionally incapacitated individual's participation in research described in subsection (a) if the research is unambiguously included in the individual's
advance directive authorizing research participation.
(f)
In considering whether an individual would have consented to participate in research were the individual able to give informed consent, a research agent, health care agent, surrogate, or
proxy decision maker may take into account any relevant information,
including:
(1) any expressed preferences of the individual regarding participation in the kind of research at issue;
(2) any expressed preferences of the individual about research participation generally;
(3) any religious or moral beliefs or personal values of the individual in relation to research participation;
(4) any behavioral or other manifestations of the attitude of
the individual toward research participation, including prior participation in research;
(5) any reactions of the individual to another individual's research participation; and
(6) any statements of the individual about the effect of research participation on the individual's family or on others who have
the same medical condition.
20-515.

AUTHORITY TO GIVE INFORMED CONSENT -

NO DIRECT MEDICAL

BENEFIT, MINOR INCREASE OVER MINIMAL RISK.

(a)
This section applies to research involving decisionally incapacitated individuals that, as determined by an IRB:
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(1) does not present a reasonable prospect of direct medical
benefit to the research subjects; and
(2) presents a minor increase over minimal risk to the research subjects.
(b)
A research agent may consent to a decisionally incapacitated individual's participation in research described in subsection (a)
if the research agent concludes, based on the advance directive authorizing research participation and other pertinent information, as
set forth in §20-514(0, that the individual would consent to participate in the research were the individual able to give informed
consent.
(c)
If a research agent is not available, a health care agent
may consent to a decisionally incapacitated individual's participation
in research described in subsection (a) if the health care agent concludes, based on direct and explicit evidence of the individual's wish
to participate in this research, as documented in accordance with standards and procedures determined by the IRB, that the individual
would consent to participate in the research were the individual able
to give informed consent.
(d)
The individual's prior participation in similar research,
when the individual was able to give informed consent, may be taken
into account by the research agent or health care agent but may not
be the sole basis on which permission is granted for the individual to
participate in the research.
(e)
No legally authorized representative other than a research agent or a health care agent may consent to a decisionally incapacitated individual's participation in research described in this
section.
20-516. AutnoRrry

TO GIVE INFORMED CONSENT NO DIRECT MEDICAL
BENEFIT, MORE THAN MINOR INCREASE OVER MINIMAL RISK.

(a)
This section applies to research involving decisionally incapacitated individuals that, as determined by an IRB:
(1) does not present a reasonable prospect of direct medical
benefit to the research subjects; and
(2) presents more than a minor increase over minimal risk to
the research subjects.
(b)
A research agent may consent to a decisionally incapacitated individual's participation in research described in subsection (a)
if:
(1) a monitor confirms that:
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(i) the research is unambiguously included in the individual's advance directive authorizing research participation; and
(ii) the research agent understands the goals and risks of
the research; and
(2) the research agent concludes, based on the advance directive authorizing research participation and other pertinent information, as set forth in §20-514(f, that the individual would consent to
participate in the research were the individual able to give informed
consent.
(c)
The monitor shall witness the process by which an investigator provides the research agent with the information required by an
IRB for informed consent.
(d)
No legally authorized representative other than a research agent may consent to a decisionally incapacitated individual's
participation in research described in this section.
20-517. AUTHORITY TO GIVE INFORMED CONSENT - LIMITATION.
Nothing in this subtitle authorizes a surrogate or a proxy decision
maker to consent to:
(1) the admission of a decisionally incapacitated individual to
a mental health facility; or
(2) a behavior modification program involving painful or invasive aversive stimuli.
20-518. WITHDRAWAL FROM RESEARCH.
A legally authorized representative who consents to a decisionally
incapacitated individual's participation in research shall:
(1) take reasonable steps to learn whether the experience of
the individual in the research is consistent with the expectations of
the legally authorized representative at. the time that consent was
granted, including expectations about -potential benefits, if any, and
risks presented by the research; and
(2) withdraw consent if:
(i) the research was initially determined to present a
reasonable prospect of direct medical benefit to the research subjects
but no longer does so for the individual;
(ii) the research presents a higher level of risk to the individual than initially expected; or
(iii) continued participation by the individual would,
considering all relevant circumstances, be detrimental to the well-being of the individual.
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(a)
An IRB may designate one or more proxy decision makers
and monitors for research conducted in the institution served by the
IRB.
(b)(1) Except as provided in paragraph (2), an IRB shall designate as a proxy decision maker or monitor a disinterested individual
who is not employed by the same institution that employs any investigator in the research about which the monitor will carry out a duty.
(2) In exceptional circumstances documented in the IRB's
minutes, an IRB may designate as a proxy decision maker or monitor
a disinterested individual who is employed in a part of the institution
organizationally distinct from that of the investigators.
(c)
Upon request of an IRB, a proxy decision maker shall
consider whether to consent to research participation by a decisionally incapacitated individual, in accordance with §20-513(e) or §20514(e).
(d)
Upon request of an IRB, a monitor shall:
(1) verify, in accordance with §20-516(b) (1), that:
(i) research is unambiguously included in an individual's advance directive authorizing research participation; and
(ii) a research agent understands the goals and risks of
the research; and
(2) witness the process by which an investigator provides the
research agent with the information required by an IRB for informed
consent.
20-520. DISCLOSURE OF DOCUMENTS AND INFORMATION.
(a)(1) An IRB shall assure that any member of the public may
obtain, upon request, a copy of the following documents related to
research involving decisionally incapacitated individuals that is approved by the IRB on or after October 1, 1998:
(i) the relevant portions of the IRB's minutes;
(ii) if not included in the IRB's minutes, a summary or
precis of the research; and
(iii) written informed consent documents approved by
the IRB.
(2) Disclosure of these documents may be made by the IRB,
or, under an agreement with the IRB, by an investigator, a sponsor of
research, or an institution with which the IRB is affiliated.
(3) The person responsible for disclosure may charge a reasonable fee for copies.
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(b)
Not later than February 15 of each year, an IRB that, during the preceding calendar year, approved research in which decisionally incapacitated individuals were intended to be subjects shall report
to the Secretary of Health and Mental Hygiene and the Attorney
General:
(1) the number of these research protocols approved; and
(2) for each research protocol, the number of decisionally incapacitated individuals who were authorized to become subjects.
The disclosures required by this subsection are in addi(c)
tion to any disclosure of information or documents related to research that is required or authorized by:
(1) federal or State statute, regulation, or policy; or
(2) the policy of the IRB, a sponsor of research, an institution
with which the IRB is affiliated, or an institution at which research
occurs.
20-521.

IMMUNITY FROM LIABILITY; PRESERVATION OF LIABILITY' UNPRO-

FESSIONAL CONDUCT.

If research involving decisionally incapacitated individuals
(a)
is authorized under this subtitle, an investigator is not subject to criminal. prosecution or civil liability or deemed to have engaged in unprofessional conduct as a result of conducting the research without the
informed consent of the research subjects.
A legally authorized representative who consents to a
(b)
decisionally incapacitated individual's participation in research as provided in this subtitle is not subject to:
(1) criminal prosecution or civil liability for that action; or
(2) liability for any costs associated with the research participation based solely on the consent.
A member of an IRB or monitor is not subject to criminal
(c)
prosecution or civil liability or deemed to have engaged in unprofessional conduct as a result of actions done in accordance with this
subtitle.
The immunity provisions of this section shall apply unless
(d)
it is shown by a preponderance of the evidence that the person did
not, in good faith, comply with the provisions of this subtitle.
(e) (1) Notwithstanding any other provision of this section, an investigator who knowingly involves a decisionally incapacitated individual in research in violation of this subtitle shall remain subject to
criminal prosecution or civil liability as otherwise provided by law.
(2) An investigator who knowingly involves a decisionally incapacitated individual in research in violation of this subtitle shall be
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deemed to have engaged in unprofessional conduct for purposes of
disciplinary action by a licensing authority.
20-522. AUTHORITY OF SECRETARY OF HEALTH AND MENTAL HYGIENE.
The Secretary may:
(1) in accordance with the Administrative Procedure Act,
adopt regulations to:
(i) designate the level of risk of a particular type of
research;
(ii) require additional disclosures to a legally authorized
representative or to the public; and
(iii) clarify other aspects of this subtitle;
(2) order the immediate suspension of any research ihvolving
decisionally incapacitated individuals that, in the judgment of the Secretary, endangers the health or safety of these individuals; and
(3) in cooperation with the Office of the Attorney General,
study the effects of this subtitle on the protection of decisionally incapacitated individuals and the conduct of research involving decisionally incapacitated individuals.
20-523. OFFICE OF THE ATTORNEY GENERAL - MODEL FORM.
After consultation with interested persons, the Office of the Attorney General shall prepare and distribute a model form of an advance directive authorizing research participation, the use of which
shall be optional.
20-524. ADVANCE DIRECTIVES EXECUTED BEFORE EFFECTIVE DATE.
An advance directive authorizing research participation made
prior to October 1, 1998 shall be given effect as provided in this
subtitle.
20-525. SHORT TITLE.
This subtitle may be cited as "The Maryland Research Consent
Act."
SECTION 2. AND BE IT FURTHER ENACTED, That this Act
shall take effect on October 1, 1998.

